A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
exenatide
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring exenatide, Byetta, type 2 diabetes, heart rate, Amylin, Lilly
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with type 2 diabetes.
- Treated with metformin and/or a thiazolidinedione.
- HbA1c between 6.5% and 9.5%, inclusive.
- Body Mass Index (BMI) > 25 kg/m^2 and < 40 kg/m^2.
Exclusion Criteria:
- Have previously received exenatide or glucagon-like peptide-1 analogs.
- Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
- Receiving beta blockers.
- Receiving treatment with a drug directly affecting gastrointestinal motility, including but not limited to Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.
- Have received treatment with systemic glucocorticoid therapy by oral, intravenous (IV), or intramuscular (IM) route within 6 weeks of screening, or are regularly treated with potent, inhaled intranasal steroids that are known to have a high rate of systemic absorption or bronchodilators.
- Have been treated with drugs that promote weight loss (for example, Adipex® [phentermine], Acomplia® [rimonabant], Xenical® [orlistat], Meridia® [sibutramine], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.
- Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening: *Insulin; *Alpha-glucosidase inhibitors (for example, Glyset® [miglitol] or Precose® [acarbose]); *Meglitinides (for example, Prandin® [repaglinide] or Starlix® [nateglinide]); *Sulfonylureas (for example, Glucotrol® [glipizide] or Micronase® [glyburide]); *Dipeptidyl peptidase IV (DPP-IV) inhibitors (for example, Januvia™ [sitagliptin])
- Have donated blood within 60 days of screening.
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Exenatide Arm
Placebo Arm
Arm Description
This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
Outcomes
Primary Outcome Measures
Change in Mean 24-hour Heart Rate From Baseline to Endpoint
Change from baseline to endpoint in average heart rate measured over 24 hours by an ambulatory blood pressure monitor.
Secondary Outcome Measures
Change in Daytime Heart Rate From Baseline to Endpoint
Change from baseline to endpoint in daytime heart rate as measured by an ambulatory blood pressure monitor
Change in Nighttime (2400-0600) Heart Rate From Baseline to Endpoint
Change from baseline to endpoint in nighttime (2400-0600) heart rate as measured by an ambulatory blood pressure monitor
Change in Mean 24 Hour Systolic Blood Pressure From Baseline to Endpoint
Change from baseline to endpoint in average systolic blood pressure measured over 24 hours by an ambulatory blood pressure monitor
Change in Mean 24 Hour Diastolic Blood Pressure From Baseline to Endpoint
Change from baseline to endpoint in average diastolic blood pressure measured over 24 hours by an ambulatory blood pressure monitor
Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint
Change from baseline to endpoint in HbA1c
Full Information
NCT ID
NCT00516074
First Posted
August 10, 2007
Last Updated
March 19, 2015
Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT00516074
Brief Title
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
Official Title
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will explore the effect of exenatide (given twice a day) versus placebo (given twice a day) treatment on change in mean 24-hour heart rate over a 12 week period of drug exposure in patients with type 2 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
exenatide, Byetta, type 2 diabetes, heart rate, Amylin, Lilly
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
54 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Exenatide Arm
Arm Type
Experimental
Arm Description
This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
Arm Title
Placebo Arm
Arm Type
Placebo Comparator
Arm Description
This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
Intervention Type
Drug
Intervention Name(s)
exenatide
Other Intervention Name(s)
Byetta, AC2993, LY2148568
Intervention Description
subcutaneous injection, 5mcg or 10mcg, twice a day
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
subcutaneous injection, volume equivalent to active, twice a day
Primary Outcome Measure Information:
Title
Change in Mean 24-hour Heart Rate From Baseline to Endpoint
Description
Change from baseline to endpoint in average heart rate measured over 24 hours by an ambulatory blood pressure monitor.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in Daytime Heart Rate From Baseline to Endpoint
Description
Change from baseline to endpoint in daytime heart rate as measured by an ambulatory blood pressure monitor
Time Frame
12 weeks
Title
Change in Nighttime (2400-0600) Heart Rate From Baseline to Endpoint
Description
Change from baseline to endpoint in nighttime (2400-0600) heart rate as measured by an ambulatory blood pressure monitor
Time Frame
12 weeks
Title
Change in Mean 24 Hour Systolic Blood Pressure From Baseline to Endpoint
Description
Change from baseline to endpoint in average systolic blood pressure measured over 24 hours by an ambulatory blood pressure monitor
Time Frame
12 weeks
Title
Change in Mean 24 Hour Diastolic Blood Pressure From Baseline to Endpoint
Description
Change from baseline to endpoint in average diastolic blood pressure measured over 24 hours by an ambulatory blood pressure monitor
Time Frame
12 weeks
Title
Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint
Description
Change from baseline to endpoint in HbA1c
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with type 2 diabetes.
Treated with metformin and/or a thiazolidinedione.
HbA1c between 6.5% and 9.5%, inclusive.
Body Mass Index (BMI) > 25 kg/m^2 and < 40 kg/m^2.
Exclusion Criteria:
Have previously received exenatide or glucagon-like peptide-1 analogs.
Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
Receiving beta blockers.
Receiving treatment with a drug directly affecting gastrointestinal motility, including but not limited to Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.
Have received treatment with systemic glucocorticoid therapy by oral, intravenous (IV), or intramuscular (IM) route within 6 weeks of screening, or are regularly treated with potent, inhaled intranasal steroids that are known to have a high rate of systemic absorption or bronchodilators.
Have been treated with drugs that promote weight loss (for example, Adipex® [phentermine], Acomplia® [rimonabant], Xenical® [orlistat], Meridia® [sibutramine], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.
Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening: *Insulin; *Alpha-glucosidase inhibitors (for example, Glyset® [miglitol] or Precose® [acarbose]); *Meglitinides (for example, Prandin® [repaglinide] or Starlix® [nateglinide]); *Sulfonylureas (for example, Glucotrol® [glipizide] or Micronase® [glyburide]); *Dipeptidyl peptidase IV (DPP-IV) inhibitors (for example, Januvia™ [sitagliptin])
Have donated blood within 60 days of screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chief Medical Officer, MD
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Halifax
State/Province
Nova Scotia
Country
Canada
Facility Name
Research Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Etten-Leur
Country
Netherlands
Facility Name
Research Site
City
Leiden
Country
Netherlands
Facility Name
Research Site
City
Rotterdam
Country
Netherlands
Facility Name
Research Site
City
Utrecht
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
20109208
Citation
Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, Braun D, Giaconia J, Malone J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010 Jan 28;9:6. doi: 10.1186/1475-2840-9-6.
Results Reference
derived
Learn more about this trial
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs